A Single Intranasal Inoculation with a Paramyxovirus-vectored Vaccine Protects Guinea Pigs Against a Lethal-dose Ebola Virus Challenge

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2006 Feb 14

PMID 16474134

Citations 54

Authors

Alexander Bukreyev

Lijuan Yang

Sherif R Zaki

Wun-Ju Shieh

Pierre E Rollin

Brian R Murphy

Peter L Collins

Anthony Sanchez

Affiliations

Soon will be listed here.

Abstract

To determine whether intranasal inoculation with a paramyxovirus-vectored vaccine can induce protective immunity against Ebola virus (EV), recombinant human parainfluenza virus type 3 (HPIV3) was modified to express either the EV structural glycoprotein (GP) by itself (HPIV3/EboGP) or together with the EV nucleoprotein (NP) (HPIV3/EboGP-NP). Expression of EV GP by these recombinant viruses resulted in its efficient incorporation into virus particles and increased cytopathic effect in Vero cells. HPIV3/EboGP was 100-fold more efficiently neutralized by antibodies to EV than by antibodies to HPIV3. Guinea pigs infected with a single intranasal inoculation of 10(5.3) PFU of HPIV3/EboGP or HPIV3/EboGP-NP showed no apparent signs of disease yet developed a strong humoral response specific to the EV proteins. When these animals were challenged with an intraperitoneal injection of 10(3) PFU of EV, there were no outward signs of disease, no viremia or detectable EV antigen in the blood, and no evidence of infection in the spleen, liver, and lungs. In contrast, all of the control animals died or developed severe EV disease following challenge. The highly effective immunity achieved with a single vaccine dose suggests that intranasal immunization with live vectored vaccines based on recombinant respiratory viruses may be an advantageous approach to inducing protective responses against severe systemic infections, such as those caused by hemorrhagic fever agents.

Citing Articles

In Vivo Investigation of Filovirus Glycoprotein-Mediated Infection in a BSL2 Setting.

Richards P, Briseno J, Brunton B, Maury W Methods Mol Biol. 2024; 2877():183-198.

PMID: 39585622 PMC: 11727417. DOI: 10.1007/978-1-0716-4256-6_13.

Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview.

Henriquez R, Munoz-Barroso I Heliyon. 2024; 10(15):e34927.

PMID: 39144987 PMC: 11320483. DOI: 10.1016/j.heliyon.2024.e34927.

A Single-Dose Intranasal Combination Panebolavirus Vaccine.

Malherbe D, Kimble J, Atyeo C, Fischinger S, Meyer M, Cody S J Infect Dis. 2023; 228(Suppl 7):S648-S659.

PMID: 37469133 PMC: 10651208. DOI: 10.1093/infdis/jiad266.

Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases.

Wang S, Liang B, Wang W, Li L, Feng N, Zhao Y Signal Transduct Target Ther. 2023; 8(1):149.

PMID: 37029123 PMC: 10081433. DOI: 10.1038/s41392-023-01408-5.

Ebola Virus Disease Vaccines: Development, Current Perspectives & Challenges.

Malik S, Kishore S, Nag S, Dhasmana A, Preetam S, Mitra O Vaccines (Basel). 2023; 11(2).

PMID: 36851146 PMC: 9963029. DOI: 10.3390/vaccines11020268.

References

Geisbert T, Hensley L, Gibb T, Steele K, Jaax N, Jahrling P . Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest. 2000; 80(2):171-86. DOI: 10.1038/labinvest.3780021. View

Geisbert T, Jahrling P . Exotic emerging viral diseases: progress and challenges. Nat Med. 2004; 10(12 Suppl):S110-21. DOI: 10.1038/nm1142. View

Pushko P, Bray M, Ludwig G, Parker M, Schmaljohn A, Sanchez A . Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine. 2000; 19(1):142-53. DOI: 10.1016/s0264-410x(00)00113-4. View

Yang Z, Duckers H, Sullivan N, Sanchez A, Nabel E, Nabel G . Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med. 2000; 6(8):886-9. DOI: 10.1038/78645. View

Teng M, Whitehead S, Bermingham A, St Claire M, Elkins W, Murphy B . Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J Virol. 2000; 74(19):9317-21. PMC: 102132. DOI: 10.1128/jvi.74.19.9317-9321.2000. View

Basler C, Wang X, Muhlberger E, Volchkov V, Paragas J, Klenk H . The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A. 2000; 97(22):12289-94. PMC: 17334. DOI: 10.1073/pnas.220398297. View

Sullivan N, Peterson M, Yang Z, Kong W, Duckers H, Nabel E . Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway. J Virol. 2004; 79(1):547-53. PMC: 538691. DOI: 10.1128/JVI.79.1.547-553.2005. View

Rouquet P, Froment J, Bermejo M, Kilbourn A, Karesh W, Reed P . Wild animal mortality monitoring and human Ebola outbreaks, Gabon and Republic of Congo, 2001-2003. Emerg Infect Dis. 2005; 11(2):283-90. PMC: 3320460. DOI: 10.3201/eid1102.040533. View

Bray M, Geisbert T . Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol. 2005; 37(8):1560-6. DOI: 10.1016/j.biocel.2005.02.018. View

10.

Jones S, Feldmann H, Stroher U, Geisbert J, Fernando L, Grolla A . Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005; 11(7):786-90. DOI: 10.1038/nm1258. View

11.

Pourrut X, Kumulungui B, Wittmann T, Moussavou G, Delicat A, Yaba P . The natural history of Ebola virus in Africa. Microbes Infect. 2005; 7(7-8):1005-14. DOI: 10.1016/j.micinf.2005.04.006. View

12.

Bukreyev A, Huang Z, Yang L, Elankumaran S, St Claire M, Murphy B . Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J Virol. 2005; 79(21):13275-84. PMC: 1262603. DOI: 10.1128/JVI.79.21.13275-13284.2005. View

13.

Volchkov V, Chepurnov A, Volchkova V, Ternovoj V, Klenk H . Molecular characterization of guinea pig-adapted variants of Ebola virus. Virology. 2000; 277(1):147-55. DOI: 10.1006/viro.2000.0572. View

14.

Sullivan N, Sanchez A, Rollin P, Yang Z, Nabel G . Development of a preventive vaccine for Ebola virus infection in primates. Nature. 2000; 408(6812):605-9. DOI: 10.1038/35046108. View

15.

Baize S, Leroy E, Mavoungou E, Fisher-Hoch S . Apoptosis in fatal Ebola infection. Does the virus toll the bell for immune system?. Apoptosis. 2001; 5(1):5-7. DOI: 10.1023/a:1009657006550. View

16.

Volchkov V, Volchkova V, Muhlberger E, Kolesnikova L, Weik M, Dolnik O . Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science. 2001; 291(5510):1965-9. DOI: 10.1126/science.1057269. View

17.

Pushko P, Geisbert J, Parker M, Jahrling P, Smith J . Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol. 2001; 75(23):11677-85. PMC: 114754. DOI: 10.1128/JVI.75.23.11677-11685.2001. View

18.

Nakaya T, Cros J, Park M, Nakaya Y, Zheng H, Sagrera A . Recombinant Newcastle disease virus as a vaccine vector. J Virol. 2001; 75(23):11868-73. PMC: 114773. DOI: 10.1128/JVI.75.23.11868-11873.2001. View

19.

Geisbert T, Pushko P, Anderson K, Smith J, Davis K, Jahrling P . Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis. 2002; 8(5):503-7. PMC: 3369765. DOI: 10.3201/eid0805.010284. View

20.

Skiadopoulos M, Surman S, Riggs J, Orvell C, Collins P, Murphy B . Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins. Virology. 2002; 297(1):136-52. DOI: 10.1006/viro.2002.1415. View